Board Change • Dec 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Frank Otto was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Frank Otto was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Frank Otto was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Frank Otto was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jul 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Frank Otto was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Frank Otto was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • May 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€155k free cash flow). Shares are highly illiquid. Negative equity (-€2.7m). Revenue is less than US$1m. Market cap is less than US$10m (CA$258.3k market cap, or US$187.5k). Minor Risk Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). New Risk • May 24
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€180k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€180k free cash flow). Shares are highly illiquid. Negative equity (-€2.6m). Revenue is less than US$1m. Market cap is less than US$10m (CA$472.4k market cap, or US$345.6k). Announcement • Apr 02
Greenrise Global Brands Inc., Annual General Meeting, May 31, 2024 Greenrise Global Brands Inc., Annual General Meeting, May 31, 2024. Board Change • Feb 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 10
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 07
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jun 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jun 08
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 31
Greenrise Global Brands Inc. to Report Fiscal Year 2022 Results on Jun 30, 2023 Greenrise Global Brands Inc. announced that they will report fiscal year 2022 results on Jun 30, 2023 Board Change • Mar 10
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 23
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 02
Third quarter 2022 earnings released Third quarter 2022 results: €0.016 loss per share. Revenue: €171.2k (up 49% from 3Q 2021). Net loss: €747.2k (flat on 3Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Board Change • Nov 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 12
An unknown buyer acquired 20% stake in CannaCare Health GmbH from Greenrise Global Brands Inc. (CNSX:XCX) for €0.25 million. An unknown buyer acquired 20% stake in CannaCare Health GmbH from Greenrise Global Brands Inc. (CNSX:XCX) for €0.25 million on November 11, 2022. Proceeds from the sale will be used for working capital purposes.
An unknown buyer acquired 20% stake in CannaCare Health GmbH from Greenrise Global Brands Inc. (CNSX:XCX) on November 11, 2022. Board Change • Oct 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Frank Otto was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 04
Greenrise Global Brands Inc., Annual General Meeting, Dec 02, 2022 Greenrise Global Brands Inc., Annual General Meeting, Dec 02, 2022. Reported Earnings • Aug 30
Second quarter 2022 earnings released: €0.014 loss per share (vs €0.02 loss in 2Q 2021) Second quarter 2022 results: €0.014 loss per share (up from €0.02 loss in 2Q 2021). Revenue: €123.0k (flat on 2Q 2021). Net loss: €596.2k (loss narrowed 3.6% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 01
First quarter 2022 earnings released: €0.012 loss per share (vs €0.017 loss in 1Q 2021) First quarter 2022 results: €0.012 loss per share (up from €0.017 loss in 1Q 2021). Revenue: €145.5k (up 26% from 1Q 2021). Net loss: €427.1k (loss narrowed 15% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 6% per year. Announcement • May 12
Greenrise Global Brands Inc. Appoints Frank Otto to the Board of Directors Greenrise Global Brands Inc. announced the appointment of Mr. Frank Otto to the board of directors of the company and the closing of the acquisition of 51% of CannaCare Health GmbH previously announced on April 5, 2022. Mr. Otto is a German media entrepreneur and a pioneer in radio and television in Germany, and co-founder of CannaCare along with the Oplesch family. Mr. Otto founded VIVA Music Television together with Time Warner and Sony Television which was later acquired by MTV. Board Change • Apr 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Claudio Morandi was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 24
Greenrise Global Brands Inc. announced that it expects to receive CAD 0.35 million in funding Greenrise Global Brands Inc. announced a non-brokered private placement of 1,000,000 units at a price of CAD 0.35 per unit for gross proceeds of CAD 350,000 on November 22, 2021. Each unit consists of one common share and one common share purchase warrant. Each warrant can be exercised to acquire one common share at a price of CAD 0.6 per share for a period of one year from the date of closing. The securities are being subject to four months and one day hold period. The warrants will also be subject to an acceleration clause whereby, in the event the volume weighted average trading price of the common shares on the Canadian Stock Exchange , or any other stock exchange on which the company’s common shares are then listed is equal to or greater than CAD 0.75 for a period of twenty consecutive trading days, the company will have the right to accelerate the expiry date of the warrants by giving written notice to the holders of the warrants that the warrants will expire on the date that is not less than thirty days from the date notice is provided by the company to the warrant holders. In connection with the offering, company may pay a finder’s fee and issue warrants to one or more arm’s length parties. Announcement • Sep 08
AMP Launches its CBD Brand, CANAVEX at YES!CON, Germany's Largest Cancer Convention AMP Alternative Medical Products Inc. announced the launch of its newly developed CBD brand, CANAVEX, sold in German pharmacies without a doctor's prescription, which are distributed thru AMP Alternative Medical Products GmbH. CBD is the most common non-psychoactive component found in the cannabis plant, and it has been found to offer a wide range of benefits. AMP created CANAVEX for cosmetic use and sold exclusively by pharmacists without a doctor's prescription. CANAVEX formulation includes high quality CBD, which is sourced from Germany and EU-GMP compliant, organic hemp seed oil and vitamin E. CANAVEX's initial products are Basic CBD 5, which contains 500mg or 5% CBD and Basic CBD 10, which contains 1,000 mg or 10% CBD and are available in 10 ml sizes. Board Change • Jul 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Claudio Morandi was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 11
AMP Alternative Medical Products Inc. announced that it has received CAD 1.6933 million in funding AMP Alternative Medical Products Inc. (CNSX:XCX) announced a non-brokered private placement of 3,386,600 common shares at a price of CAD 0.50 per share for gross proceeds of CAD 1,693,300 on February 10, 2021. The transaction included participation from insiders of the company for CAD 250,000. The company paid finder; fee of CAD 52,465 and issued 104,930 warrants. Each finder warrant will entitle the holder to purchase a share at a price of CAD 0.50 for a period of 6 months. Securities issued will be subject to hold period of four months expiring on June 10, 2021. Announcement • Jan 28
AMP German Cannabis Group Inc. and CC Pharma GmbH Enter into Strategic Co-Promotion Agreement for the Sale of Medical Cannabis in Germany AMP German Cannabis Group Inc. ("AMP") and Aphria Inc.'s wholly-owned German subsidiary, CC Pharma GmbH ("CC Pharma"), have entered into a strategic agreement (the "Co-Promotion Agreement") covering joint marketing of sales for Aphria brand medical cannabis products for the German market. The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany. In addition, AMP will organize with the support of CC Pharma, "information events" in Germany to market Aphria branded products to doctors and pharmacists. Is New 90 Day High Low • Jan 07
New 90-day high: CA$0.40 The company is up 21% from its price of CA$0.33 on 07 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 6.0% over the same period. Announcement • Nov 06
AMP German Cannabis Group Enters into Long Term Supply Agreement with Danish Medical Cannabis Producer Schroll Medical AMP German Cannabis Group Inc. and Schroll Medical ApS ("Schroll"), announced that they have entered into a non-exclusive, three-year supply agreement for bulk and packaged EU-GMP cannabis flower which shall be branded under the AMP medical cannabis brand when offered in the German market. Schroll's large-scale greenhouse cultivation facility located in Årslev, Denmark, was EU-GMP certified by the Danish Medicines Agency in November 2019 and began production this year. The facility employs over 35 people and can produce 6,000 kilograms of dried medical cannabis flowers annually. AMP completed the on-site audit of Schroll's production plant last week. AMP will register products purchased from Schroll with The Federal Institute for Drugs and Medical Devices (BfArM) and has applied for an irradiation license ("AMRadV License") for Schroll products, which AMP plans to sell in the German market. Announcement • Sep 16
AMP German Cannabis Group Inc. Appoints Marc Wälken as Sales Director AMP German Cannabis Group Inc. announced the appointment of Mr. Marc Wälken as Sales Director, effective immediately. Mr. Wälken joins AMP from Spectrum Therapeutics, a brand of Canopy Growth Germany GmbH, a wholly-owned subsidiary of Canopy Growth Corporation, where he was Areas Sales Manager and Key Account Manager. Prior to that, Mr. Wälken was a sales representative for Roche Pharma AG, the German division of The Roche Group. Mr. Wälken is responsible for implementing and managing sales strategies to introduce AMP's branded cannabis products and build AMP's national sales team. The development of a national sales team is important in generating strong revenue growth. Announcement • Sep 09
AMP German Cannabis Group Inc. announced that it expects to receive CAD 0.5 million in funding AMP German Cannabis Group Inc. (CNSX:XCX) announced a non-brokered private placement of 1428571 shares at an issue price of CAD 0.35 per share for gross proceeds of up to CAD 500,000 on September 8, 2020. In connection with the transaction, the company may pay a finder’s fee and warrants to one or more arm’s length parties. All securities issued pursuant to the transaction will be subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws.